The p.Val160Met variant has recently been found to be associated with a mutation in TMPRSS2, particularly in terms of the risk of prostate cancer (FitzGerald et al., 2008) and the examination of this variant in patients may shorten the diagnosis time in high-risk individuals (Giri et al., 2011). This evidence concerns the gene TMPRSS2 and prostate carcinoma.